Success of the company’s strategic repositioningSales of theranostics products x 3.6, totaling €1.4 million Acceleration in sales of in house products: +26%, 61% of total revenuesRobust growth of international sales: 41% of total revenuesStrong increase…
Croissy-Beaubourg and Montpellier, January 15, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announces that it has renewed the Standby Equity Facility (SEF®) arranged with Société Générale,…
Croissy-Beaubourg and Montpellier, January 6, 2015 – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specializing in theranostics and in vitro diagnostics, announces today its financial reporting schedule for 2015.Financial publications will be released after…